Sumanta K. Pal, MD: Let's Get More Patients With Rare Tumors Into Clinical Trials

In My Opinion

Sumanta K. Pal, MD, of City of Hope, talks about the need for investigators across the country to enroll their patients with rare tumors in clinical trials. He describes a trial he is leading for papillary kidney cancer and how others can join his efforts.

Owen A. O’Connor, MD, PhD, on Issues in Immunotherapy

Owen A. O'Connor, MD, PhD, of Columbia University Medical Center, shares his perspective on immunotherapy for patients with late-stage cancer in the context of a clinical trial set...

Issues in Oncology

Cost of Care

Karim Fizazi, MD, PhD: We Need to Find a Way to Make Cancer Drugs Affordable

Karim Fizazi, MD, PhD, of Gustave Roussy, urges governments, insurers, and pharmaceutical companies to work together in order to find a way to make antican...

Issues in Oncology

Andrew D. Seidman, MD, on Embracing Computer-Assisted Decision-Making

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discusses the benefits of decision support tools, especially for the oncologist who treats a variety of canc...

Issues in Oncology

Palliative Care

Immunotherapy

A. Oliver Sartor, MD, on Issues in Immunotherapy

A. Oliver Sartor, MD, of Tulane University, speaks anecdotally about immunotherapy for prostate cancer and shares his experiences in speaking to patients with late-stage dise...

Issues in Oncology

Cost of Care

Allen S. Lichter, MD, and Mark J. Ratain, MD, on Better Dosing, Lower Cost: Improving Cancer Care and Value

Allen S. Lichter, MD, Board Chair of the Value in Cancer Care Consortium, and Mark J. Ratain, MD, of the University of Chicago, discuss the benefits—and chal...

Apr

Today In Oncology

KEYNOTE-042: Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic NSCLC With PD-L1 Expression ≥ 1%

;

Sumanta K. Pal, MD: Let's Get More Patients With Rare Tumors Into Clinical Trials

Related Videos

Owen A. O’Connor, MD, PhD, on Issues in Immunotherapy

Karim Fizazi, MD, PhD: We Need to Find a Way to Make Cancer Drugs Affordable

Andrew D. Seidman, MD, on Embracing Computer-Assisted Decision-Making

A. Oliver Sartor, MD, on Issues in Immunotherapy

Allen S. Lichter, MD, and Mark J. Ratain, MD, on Better Dosing, Lower Cost: Improving Cancer Care and Value

Does Intake of Dietary Fat Increase Risk of Skin Cancer?

FDA Approves Pembrolizumab Plus Axitinib for First-Line Treatment of Advanced Renal Cell Carcinoma

Cervical Cancer Subtype Rising in Some Populations

Deep-Learning Model May Improve Predictions of Survival and Specific Outcomes in Lung Cancer

KEYNOTE-042: Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic NSCLC With PD-L1 Expression ≥ 1%